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Introduction
Selective enhancement (or activation) of the immune sys-
tem by novel small molecules may be a potential therapeu-
tic approach for the treatment of cancer. RORgt (Retinoic
Acid Receptor-related orphan receptor) is the key tran-
scription factor for the development of CD4+ Th17 cells,
CD8+ Tc17 cells and IL-17+ innate immune cells including
gδ T cells. A member of the nuclear receptor superfamily,
RORg modulates the expression of cytokines, chemokines
and their receptors to induce a pro-inflammatory environ-
ment. RORg can interact with other lineage-associated
transcription factors resulting in developmental plasticity
which reinforces immunity and limits immunosuppressive
mechanisms. These activities suggest that the activation of
RORg may enhance anti-tumor immune responses and
Th17 and Tc17 cells have been reported to have potent
anti-tumor effects in vivo.
Results
We have discovered a series of synthetic RORg agonist
compounds that enhance the activity of an RORg-depen-
dent reporter and increase IL-17A, IL-17F, IL-22 and GM-
CSF production by murine and human T cells. CD4+ T
cell stimulation with cytokine cocktails including TGFb in
vitro can generate Th17 and Treg cells; the addition of
RORg agonists decreases the expression FOXP3 while con-
comitantly increasing IL-17 and GM-CSF mRNA expres-
sion. In addition, stimulation of T cells in the presence of
RORg agonist compounds generates effector T cells that
resist PD-1/PD-L1-mediated inhibition of proliferation
and cytokine production. Taken together, the enhanced
production of cytokines, decreased generation of Treg
cells and resistance to PD-1 checkpoint inhibition sup-
ports RORg agonists having potential anti-tumor activities.
Indeed, OVA-specific CD8+ T cells activated in vitro with
RORg agonist compounds reduced growth of OVA-
expressing EG7 and B16F10 tumors more effectively than
cells stimulated without RORg agonist. Flow cytometric
analysis of tumors over time showed increased numbers of
agonist treated cells present as tumor infiltrating lympho-
cyte (TILs). A higher percentage of these TILs were IL-17+
with increased mean fluorescent intensity for IL-17. Ago-
nist treated TILs had increased expression of CD62L and
decreased expression of PD-1 suggesting that agonist
treatment preserves a less differentiated, more central
memory phenotype that may be less susceptible to check-
point inhibition and have increased survival capacity.
Conclusions
RORg agonist compounds enhance immune-associated anti-
tumor pathways, decrease immunosuppressive mechanisms
and induce effector T cells which decrease tumor growth.
Immune enhancement by RORg agonists may therefore
represent a unique anti-tumor approach which could also
complement other immunotherapy approaches.
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